scFv Panel for FTD Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment strategies for neurodegenerative diseases like frontotemporal dementia (FTD) are hindered by the complexity of protein misfolding and aggregation, with multiple proteins involved, making it difficult to identify effective biomarkers and develop targeted therapies.
Innovation Solution
Development of a panel of single-chain variable fragments (scFvs) that selectively recognize protein variant biomarkers associated with FTD, including TDP-43, beta-amyloid, and tau, allowing for personalized diagnostic tests and therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple proteins are monitored for diagnosis, then diagnostic coverage is improved, but test complexity increases
Solution Approach 1:
The panel of scFvs is designed to detect multiple different protein variants (TDP-43, tau, beta-amyloid, alpha-synuclein) using a unified assay platform, allowing one test system to perform multiple diagnostic functions simultaneously, thereby improving diagnostic coverage without proportionally increasing complexity
Solution Approach 2:
The diagnostic approach segments the complex task of detecting multiple proteins into individual scFv components, each targeting a specific protein variant. This modular segmentation allows systematic detection of different proteinopathies while maintaining manageable test complexity through standardized assay procedures
2Loss of information
If multiple protein variants are detected, then biomarker identification is improved, but measurement precision requirements increase
Solution Approach 1:
Each scFv in the panel is engineered with specific binding characteristics tailored to recognize particular protein variants (e.g., TDP-43 vs. tau vs. beta-amyloid). This local optimization of binding specificity ensures high measurement precision for each target while maintaining the ability to detect multiple biomarkers across the panel
Solution Approach 2:
The patent uses single-chain variable fragments (scFvs) as simplified copies of full antibodies, retaining the essential antigen-binding capability while reducing molecular complexity. This allows precise detection of multiple protein variants through smaller, more manageable binding agents that can be produced and standardized more easily
3Reliability
If personalized diagnostic approaches are implemented, then treatment effectiveness is improved, but diagnostic cost increases
Solution Approach 1:
The scFv panel serves as a universal diagnostic tool that can identify multiple different proteinopathies (TDP-43, tau, beta-amyloid, alpha-synuclein) within a single test platform. This multi-functionality enables personalized medicine approaches by determining which specific protein variant is driving each patient's symptoms, allowing targeted therapies to be selected based on actual biomarker presence rather than empirical treatment trials
Solution Approach 2:
The patent changes the diagnostic parameter from generic cognitive assessment to specific protein variant detection. By measuring the presence and levels of particular proteinopathies rather than just clinical symptoms, the test provides actionable information that directly guides treatment selection, improving the cost-effectiveness of personalized approaches through more precise biomarker-based decision making
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFvs demonstrate strong sensitivity and specificity for FTD cases, correlating with disease progression and indicating potential therapeutic targets, enabling more effective diagnosis and treatment strategies tailored to individual patients.
Implementation Method 1
a panel of 14 scFvs. Seven of the scFvs bound select protein variants of TDP-43, three bound select oligomeric variants of beta-amyloid, two bound select oligomeric variants of tau and two bound select oligomeric variants of alpha-synuclein
Data Source
AI summary
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.